I eat half an avocado most mornings, so when a headline promised “surprising heart benefits” from an avocado and a cup of mango every day, I felt a small glow of vindication. It faded once I asked the question every diet study owes you an answer to: compared with what? The fruit group’s arteries did improve on a standard ultrasound test, but roughly half the gap between the groups came from the comparison group’s arteries doing worse after eight weeks on a low-fat, low-fiber menu, in a trial paid for by the two boards that market the fruit.
Researchers at the Illinois Institute of Technology randomized 82 adults with prediabetes and overweight or obesity into two groups and fed them for eight weeks, with meal plans covering 75 percent of each person’s daily calorie needs, according to the press release. One menu built in a Hass avocado and a cup of fresh mango every day, while the other swapped in calorie-matched carbohydrate foods. Chelsea Preiss, Britt Burton-Freeman and colleagues published the results in the Journal of the American Heart Association.
Their main test, flow-mediated dilation, is one of my favorite bits of physiology because you can practically watch it happen. A cuff squeezes the upper arm shut for a few minutes. When it lets go, blood pours back into the brachial artery, the rush drags along the vessel lining, and the lining answers with nitric oxide, which tells the muscle in the artery wall to relax. The artery widens, and how much it widens, as a percentage, is a read on how well that inner lining is working. So why would a fatty green fruit and a sweet orange one let an artery open wider? The fruit group ate significantly more fiber, vitamin C and monounsaturated fat, per a summary of the paper, which makes those nutrients the obvious suspects. I buy the biology. I also notice that the control menu was built low in fat and fiber, so two of those three nutrients were stacked in the fruit’s favor before anyone took a bite.
The trial’s registry record is unusually candid about this. The control meal plans were “matched in calories (but not macronutrients or fiber)” to the fruit arm, and the paper describes the control as “an energy-equivalent diet containing low-fat and low-fiber foods.” So the fruit was competing against low-fiber carbohydrate foods rather than a well-built diet, and a menu like that sits closer to how plenty of Americans already eat than any nutritionist would like.
That design shows up in the numbers. The between-group difference in FMD change was 2.11 percentage points (P = 0.008). The fruit group rose by about 1 point to finish at 6.7 percent, while the control group fell to 4.6 percent, according to the release. If one arm climbed about a point and the gap between the arms was 2.11, the control arm’s decline supplied roughly the other half. That’s worth knowing, because a good share of “avocado and mango improve arteries” turns out to be a comparison group whose arteries slid on the menu it was assigned.
Blood pressure tells a narrower version of the same story. Central blood pressure was a primary outcome on the registry, and for central diastolic pressure the difference between groups came in at P = 0.07, short of significance, per the paper summary. The significant finding was ordinary cuff (brachial) diastolic pressure, at P = 0.03, particularly in men. The release leads with the men: central pressure up about 5 mmHg on the control diet, down about 1.9 on the fruit. An effect that shows up mainly in one subgroup doesn’t prove men benefit more than women, since that takes a direct test of the difference, and the publicity reports none. Cholesterol, blood sugar and inflammation markers showed no significant difference between the groups, and body weight held steady. In a trial built around people with prediabetes, blood sugar failing to separate deserves more than a passing line.
I went to the registry expecting a single headline outcome and found 12 listed as primary in the record first posted in April 2022: flow-mediated dilation, pulse wave velocity and central blood pressure, then glucose, insulin, lipids, three inflammation markers, two brain and growth markers (BDNF and IGF-1) and kidney function. Below those sit secondary outcomes on retinal blood vessels and a battery of memory and reasoning tests. The bluntest correction for 12 primary outcomes divides the usual 0.05 threshold by 12, which puts the bar near 0.004, and the FMD result’s 0.008 doesn’t clear it. The release that carried this trial into the news names the FMD win, a diastolic win mostly in men, an improvement in the kidney marker eGFR and the metabolic nulls. On pulse wave velocity, BDNF, IGF-1, the eye scans and the cognitive tests, it says nothing. When a trial lists that many outcomes and the marketing crowns one, readers deserve the rest of the scorecard.
Then there’s the money. The study was paid for by an unrestricted grant from the National Mango Board and the Hass Avocado Board, and the trial registry lists both boards as collaborators. Both boards say they had no role in the study design or findings, according to the release, which went out February 24 through Wild Hive, a PR firm. The same story resurfaced on ScienceDaily on November 3, still credited to Wild Hive, more than eight months later. Burton-Freeman has worked with avocado money before: her 2018 post-meal avocado trial in Nutrients “was supported by the Hass Avocado Board,” and its disclosure states that she “is a member of Avocado Nutrition Science Advisory.” None of that makes the data fake. It does mean the people selling the fruit paid for a trial that pitted it against a menu built low in fat and fiber, and that choice of comparison shapes how good the fruit looks.
A much larger avocado study offers a check, with a caveat about how different it was. The Habitual Diet and Avocado Trial gave 1,008 adults with large waistlines, not specifically people with prediabetes, either one avocado a day or their usual diet for six months, and it measured visceral belly fat by MRI rather than artery function. Visceral fat didn’t differ between the groups, though the avocado group saw modest drops in total and LDL cholesterol. That can’t overturn an FMD result. It does show what avocado looks like when it’s compared with what people actually eat instead of a menu built low in fiber: a decent food with small effects and no miracle attached.
What I’d still carry out of this trial is pro-food. In eight weeks, with calories matched and body weight steady, a menu built around fruit carrying fat, fiber and vitamin C beat a low-fat, low-fiber carbohydrate menu on how an artery behaves, in people already sliding toward diabetes. Burton-Freeman calls that “the power of food-first strategies,” and I’m with her on it. What the trial can’t say, as even ScienceDaily’s write-up concedes, is whether the pair does better than either fruit alone, and it never tested any other fruit at all. That’s the question a board selling one specific fruit has the least reason to fund.
I’m keeping my half avocado and trading my afternoon crackers for whatever fruit is ripe. That’s my own bet on fiber, not something this trial proved, and I’m making it without waiting for a mango board to pay for the answer.
Sources
- Journal of the American Heart Association: Preiss, Burton-Freeman et al., avocado and mango in adults with prediabetes (2026)
- ClinicalTrials.gov: NCT05353790, Dietary Exchanges With Avocado and Mango in Pre-diabetes
- EurekAlert!: Wild Hive press release on the avocado-mango trial (February 24, 2026)
- Medical Dialogues: summary of trial results, FMD and blood pressure statistics
- ScienceDaily: “Scientists discover surprising heart benefits of eating avocado and mango every day”
- Nutrients: Park, Edirisinghe and Burton-Freeman, avocado dose-response trial on post-meal cardiometabolic markers (2018)
- JAHA: Habitual Diet and Avocado Trial, one avocado per day versus habitual diet on visceral adiposity (2022)